Tourmaline Bio

TRML

Market cap $1.22B

Overview Fund Activity

47.61 USD

+0.01

0.02%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

47.60

-0.01

0.02%

1 day

0.02%

5 days

76.92%

1 month

121.65%

3 months

139.25%

6 months

192.62%

Year to date

130.67%

1 year

167.32%

5 years

-70.7%

10 years

-70.7%

About: Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Employees: 77

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

400% more call options, than puts

Call options by funds: $5K | Put options by funds: $1K

6% more capital invested

Capital invested by funds: $364M [Q1] → $385M (+$20.5M) [Q2]

10% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 31

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

1% more funds holding

Funds holding: 107 [Q1] → 108 (+1) [Q2]

0.46% more ownership

Funds ownership: 93.23% [Q1] → 93.68% (+0.46%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$48

0% upside

Avg. target

$48

1% upside

High target

$48

1% upside

8 analyst ratings

0 positive

0%

8 neutral

100%

0 negative

0%

Piper Sandler Yasmeen Rahimi	$48	Neutral Downgraded	11 Sep 2025
Truist Securities Robyn Karnauskas	$48	Hold Downgraded	10 Sep 2025
Guggenheim Yatin Suneja	$48	Neutral Downgraded	10 Sep 2025
HC Wainwright & Co. Yi Chen	$48	Neutral Downgraded	10 Sep 2025
Chardan Capital Daniil Gataulin	$48	Neutral Downgraded	10 Sep 2025
LifeSci Capital	$48	Market Perform Downgraded	9 Sep 2025
Jefferies Roger Song	$48	Hold Downgraded	9 Sep 2025
Wedbush Laura Chico	$48	Neutral Downgraded	9 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 16 articles about TRML published over the past 30 days

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Tourmaline Bio, Inc. (NasdaqGS: TRML) to Novartis AG. Under the terms of the proposed transaction, shareholders of Tourmaline will receive $48.00 in cash for each share of Tourmaline that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequat.

TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML

Zacks Investment Research

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

This Small Biotech Stock Is Surging Today. Here's Why.

Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.

This Small Biotech Stock Is Surging Today. Here's Why.

Investors Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion

Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion. Tourmaline shares jumped nearly 58%, trading at $48 per share, compared with Monday's closing price of $30.18.

Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit

This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.

Novartis agrees to acquire Tourmaline Bio in an all-cash deal worth around $1.4 billion.

This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.

Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal

Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highlighting confidence in Tourmaline's cardiovascular drug pipeline.

Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft Deal

TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Tourmaline Bio, Inc. (NASDAQ: TRML) to Novartis AG for $48.00 per share in cash is fair to Tourmaline shareholders. Halper Sadeh encourages Tourmaline shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Tourmaline.

TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders

Proactive Investors

Novartis strikes $1.4bn deal for Tourmaline Bio

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthening its push into cardiovascular medicine with a late-stage anti-inflammatory drug candidate. The Swiss pharmaceutical group will pay $48.00 a share, a 59% premium to Tourmaline's closing price on Monday and 127% above its 60-day average.

Novartis strikes $1.4bn deal for Tourmaline Bio

Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible breaches of fiduciary duty and other violations of law in its transaction with a Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Tourmaline will $48.00 per share in cash at closing, or a total equity value of approximately $1.4 billio.

Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders

See News Rankings

Charts implemented using Lightweight Charts™